Basic Information
| LncRNA/CircRNA Name | LINC00152 |
| Synonyms | CYTOR, C2orf59, LINC00152, NCRNA00152 |
| Region | GRCh38_2:87454781-87636740 |
| Ensemble | ENSG00000222041 |
| Refseq | NR_024204 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown etc. |
| Sample | cell lines (SMMC-7721, Hep3B, HCCLM3 and HepG2), HCC tissues |
| Expression Pattern | down-regulated |
| Function Description | The results indicated that the expression level of LINC00152 was positively correlated with tumor size (OR=5.19, 95% CI: 2.33-11.52, p<.0001), TNM stage (OR=3.12, 95% CI: 1.77-5.51, p<.0001) and lymph node metastasis (OR=3.41, 95% CI: 2.13-5.48, p<.00001). Moreover, elevated LINC00152 could predict unfavorable OS with pooled HR of 1.66 (95% CI: 1.29-2.13, p<.0001) and poor DFS (HR=2.13, 95% CI: 1.39-3.25, p=.0005) in cancer patients. CONCLUSION: LINC00152 was correlated with advanced clinicopathological features and poor prognosis as a novel predictive biomarker in various cancers. |
| Pubmed ID | 29617624 |
| Year | 2018 |
| Title | Long noncoding RNA LINC00152 as a novel predictor of lymph node metastasis and survival in human cancer: a systematic review and meta-analysis. |
External Links
| Links for LINC00152 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |